Pharmacokinetics and Dynamics of Dexmedetomidine as Adjuvant in TAP Block

Assiut University24 enrolled

Overview

TAP-block has been shown to be a safe and effective postoperative analgesia method in a variety of general. Dexmedetomidine is a selective α2 agonist with 8 times more affinity for α2 adrenergic receptors compared to clonidine and possesses all the properties of α2 agonist without respiratory depression. Dexmedetomidine has been focus of interest for its broad spectrum (sedative, analgesic and anesthetic sparing) properties, making it a useful and safe adjunct in many clinical applications.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Postoperative Pain

Interventions

DexmedetomidineDRUG

20 ml of 0.5 % bupivacaine plus dexmedetomidine 1 μg•kg-1

bupivacaineDRUG

20 ml of 0.5 % bupivacaine

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 24 ASA I-II * patients (age 18-60 years * weight 50-89 kg Exclusion Criteria: * a known allergy to the study drugs * significant cardiac * respiratory, renal or hepatic diseases * bleeding diathesis

Locations (1)

South Egypt Cancer instIitute

Asyut, Egypt

Outcomes

Primary Outcomes

measure dexmedetomidine level into systemic circulation after local administration

assessment of systemic dexmedetomidine level after local administration in TAP block after 15 minutes after giving the block, 30 min, 45 min, 1hrs, 2hrs, 4hrs and 6

Time frame: up to 6 hours

Secondary Outcomes

total dose of IV PCA morphine consumption in the first 24 h postoperative

postoperative morphine consumption

Time frame: 24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.